

Page 4, lines 14-17, change "[1S-[1R-(R),2S*])-N¹-[3-[[[(1,1 - dimethylethyl)amino]carbonyl](2-methylpropyl)amino]-2-hydroxy-1 -(phenylmethyl)propyl]-2-[(2quinolinylcarbonyl)amino]-butanediamide;" to read:

Q2 [1S-[1R-(R),2S*])-N¹-[3-[[[(1,1 -dimethylethyl)amino]carbonyl](2-methylpropyl)amino]-2-hydroxy-1 -(phenylmethyl)propyl]-2-[(2quinolinylcarbonyl)amino]-butanediamide;

Page 11, lines 11-15 please change "[[(2S,3S,5S)-5-(N-(N-((N-methyl-N-((2-isopropyl-4-thiazolyl)methyl)amino)carbonyl)-L-valinyl)amino)-2-(N-((5-thiazolyl)methoxy-carbonyl)-amino)-amino-1,6-diphenyl-3-hydroxyhexane]" to read:

Q3 [[(2S,3S,5S)-5-(N-(N-((N-methyl-N-((2-isopropyl-4-thiazolyl)methyl)amino)carbonyl)-L-valinyl)amino)-2-(N-((5-thiazolyl)methoxy-carbonyl)-amino)-amino-1,6-diphenyl-3-hydroxyhexane] - -.

IN THE CLAIMS:

Please cancel Claims 3-4 and 12-18, without prejudice to the patentability thereof.

Please replace Claim 1 with the following:

Q4 Claim 1. (amended) A pharmaceutical composition comprising a solid dispersion of an HIV protease inhibitor or a combination of HIV protease inhibitors in a water soluble carrier wherein the HIV protease inhibitor or the combination of HIV protease inhibitors is in amorphous form in the dispersion.

Please replace Claim 5 with the following:

Q5 5. (amended) The composition of Claim 2 wherein said HIV protease inhibitor is selected from the group consisting of:

(2S,3S,5S)-5-(N-(N-((N-methyl-N-((2-isopropyl-4-thiazolyl)methyl)amino)carbonyl)-L-valinyl)amino)-2-(N-((5-thiazolyl)methoxy-carbonyl)-amino)-1,6-diphenyl-3-hydroxyhexane (ritonavir);

(2S, 3S, 5S)-2-(2,6-Dimethylphenoxyacetyl) amino-3-hydroxy-5-[2S-(1-tetrahydro-pyrimid-2-onyl)-3-methyl butanoyl] amino-1,6-diphenylhexane (ABT-378);

N-(2(R)-hydroxy-1 (S)-indanyl)-2(R)-phenylmethyl

-4(S)-hydroxy-5-(1-(4-(3-pyridylmethyl)-2(S)-N'-(t-butylcarboxamido)-piperazinyl))-pentaneamide (indinavir);

N-tert-butyl-decahydro-2-[2(R)-hydroxy-4-phenyl-3(S)-[[N-(2-quinolylcarbonyl)-L-asparaginy]amino]butyl)-(4aS,8aS)-isoquinoline-3(S)-carboxamide (saquinavir);

5(S)-Boc-amino-4(S)-hydroxy-6-phenyl-2(R)-phenylmethylhexanoyl-(L)-Val-(L)-Phe-morpholin-4-ylamide;

1-Naphthoxyacetyl-beta-methylthio-Ala-(2S, 3S)- 3-amino-2-hydroxy-4-butanoyl 1,3-thiazolidine-4- t-butylamide;

5-isoquinolinoxyacetyl-beta-methylthio-Ala-(2S,3S)-3-amino-2-hydroxy-4-butanoyl-1,3-thiazolidine-4-t-butylamide;

[1S-[1R-(R-),2S*] -N'-[3-[[[(1,1 -dimethylethyl)amino]carbonyl](2-methylpropyl)amino]-2-hydroxy-1 -(phenylmethyl)propyl]-2-[(2quinoliny]carbonyl)amino]-butanediamide;

VX-478; DMP-323; DMP-450; AG1343 (nelfinavir);

BMS 186,318; SC-55389a; BILA 1096 BS; U-140690, and combinations thereof.

Please replace Claim 6 with the following:

6. (amended) The composition of Claim 2 wherein said HIV protease inhibitor is (2S,3S,5S)-5-(N-(N-((N-methyl-N-((2-isopropyl-4-thiazolyl)methyl)amino)carbonyl)-L-valinyl)amino)-2-(N-((5-thiazolyl)methoxy-carbonyl)-amino)-1,6-diphenyl-3-hydroxyhexane (ritonavir).

Please replace Claim 8 with the following:

8. (amended) The composition of Claim 2 wherein said HIV protease inhibitor is a combination of (2S,3S,5S)-5-(N-(N-((N-methyl-N-((2-isopropyl-4-thiazolyl)methyl)amino)carbonyl)-L-valinyl)amino)-2-(N-((5-thiazolyl)methoxy-carbonyl)-amino)-1,6-diphenyl-3-hydroxyhexane (ritonavir) and (2S,3S,5S)-2-(2,6Dimethylphenoxyacetyl)amino-3-hydroxy-5-[2S-(1-tetrahydro-pyrimid-2-onyl)-3-methyl butanoyl] amino-1,6-diphenylhexane (ABT-378).

Please replace Claim 20 with the following:

20. (amended) The method of Claim 19 wherein said HIV protease inhibitor is selected from the group consisting of (2S,3S,5S)-5-(N-(N-((N-methyl-N-((2-isopropyl-4-thiazolyl)methyl)amino)carbonyl)-L-valinyl)amino)-2-(N-((5-thiazolyl)methoxy-carbonyl)-amino)-1,6-diphenyl-3-hydroxyhexane (ritonavir) and (2S,3S,5S)-2-(2,6-Dimethylphenoxyacetyl)amino-3-hydroxy-5-[2S-(l-tetrahydro-pyrimid-2-onyl)-3-methyl butanoyl] amino-1,6-diphenylhexane (ABT-378).

Please replace Claim 21 with the following:

21. The method of Claim 19 wherein said HIV protease inhibitor is a combination of (2S,3S,5S)-5-(N-(N-((N-methyl-N-((2-isopropyl-4-thiazolyl)methyl)amino)carbonyl)-L-valinyl)amino)-2-(N-((5-thiazolyl)methoxy-carbonyl)-amino)-1,6-diphenyl-3-hydroxyhexane (ritonavir) and (2S,3S,5S)-2-(2,6Dimethylphenoxyacetyl)amino-3-hydroxy-5-[2S-(l-tetrahydro-pyrimid-2-onyl)-3-methyl butanoyl] amino-1,6-diphenylhexane (ABT-378).

Please add the following new claims:

- - 22. (new claim) A pharmaceutical composition comprising a dispersion of (2S,3S,5S)-5-(N-(N-((N-methyl-N-((2-isopropyl-4-thiazolyl)methyl)amino)carbonyl)-L-valinyl)amino)-2-(N-((5-thiazolyl)methoxy-carbonyl)-amino)-1,6-diphenyl-3-hydroxyhexane (ritonavir) in a water soluble carrier wherein the ritonavir is in amorphous form in the dispersion.

23. (new claim) The composition of Claim 22 wherein said water soluble carrier is polyethylene glycol (PEG).

24. (new claim) A pharmaceutical composition comprising a dispersion of (2S,3S,5S)-2-(2,6-Dimethylphenoxyacetyl)amino-3-hydroxy-5-[2S-(l-tetrahydro-pyrimid-2-onyl)-3-methyl butanoyl] amino-1,6-diphenylhexane (ABT-378) in a water soluble carrier wherein the ABT-378 is in amorphous form in the dispersion.